alfuzosin (uroxatral) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.   NCATS

Chemistry

  • SMILES: COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3
  • InChIKey: WNMJYKCGWZFFKR-UHFFFAOYSA-N
  • Mol. Mass: 389.46
  • ALogP: 1.35
  • ChEMBL Molecules:
    alfuzosin  
    alfuzosin hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1370 - $19.7233

Australia

$1.3377
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

afuzosin | alfetim | alfusozine | alfutral sr | alfuzocine | alfuzosin | alfuzosina | alfuzosine | alfuzosin hcl | alfuzosin hydrochloride | alfuzosinum | alphuzosine | benestan | benestan ret | besavar xl | fuzatal xl | kelanu xl | (±)-n-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide | n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide | n-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide | sl 77 | sl-7749910 | sl-77499-10 | urion | urion s | urotraxal | uroxatral | vasran xl | xatral | xatral sr | zufal xl

Organizations (43)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Prostatic Hyperplasia

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Choroid Diseases (Phase 4)

Constipation (Phase 2)

Erectile Dysfunction (Phase 3)

Healthy Volunteers (Phase 1)

Hydronephrosis (Phase 3)

Kidney Calculi (Phase 3)

Lower Urinary Tract Symptoms (Phase 4)

Multiple Sclerosis (Phase 2/Phase 3)

Nephrolithiasis (Phase 2)

Prostatic Diseases (Phase 4)

Prostatic Hyperplasia ()

Prostatic Neoplasms (Phase 3)

Prostatitis (Phase 3)

Pupil Disorders (Phase 4)

Renal Colic (Phase 4)

Ureteral Diseases (Phase 4)

Ureterolithiasis (Phase 2)

Urinary Bladder Diseases (Phase 3)

Urinary Bladder, Neurogenic (Phase 3)

Urinary Calculi (Phase 3)

Urinary Retention (Phase 3)

Urination Disorders (Phase 3)

Urolithiasis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue